Search results
Showing 61 to 75 of 354 results for covid
What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people...
Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management
(VTE) prophylaxis for people who have been discharged after treatment for COVID-19? Any explanatory notes(if applicable)...
May 2021 The COVID-19 pandemic has greatly affected diagnostic and treatment pathways resulting
combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19? Any explanatory notes(if...
to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their...
Recommendation ID NG191/12 Question In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are...
How to use our content for your own purpose. Reuse our guidance, advice, collections and documents.
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised...
awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher...
This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.
pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors...
Find out more about the progress made in implementing NICE guidance on diagnostic pathology
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .